Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Jan 12;1(1):CD009403.
doi: 10.1002/14651858.CD009403.pub2.

Vitamin B and its derivatives for diabetic kidney disease

Amit D Raval  1 , Divyesh Thakker, Arohi N Rangoonwala, Deval Gor, Rama Walia
Affiliations
Meta-Analysis

Vitamin B and its derivatives for diabetic kidney disease

Amit D Raval et al. Cochrane Database Syst Rev. .

Abstract

Background: Diabetes is a leading cause of end-stage kidney disease (ESKD) mainly due to development and progression of diabetic kidney disease (DKD). In absence of definitive treatments of DKD, small studies showed that vitamin B may help in delaying progression of DKD by inhibiting vascular inflammation and endothelial cell damage. Hence, it could be beneficial as a treatment option for DKD.

Objectives: To assess the benefits and harms of vitamin B and its derivatives in patients with DKD.

Search methods: We searched the Cochrane Renal Group's Specialised Register to 29 October 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.

Selection criteria: We included randomised controlled trials comparing vitamin B or its derivatives, or both with placebo, no treatment or active treatment in patients with DKD. We excluded studies comparing vitamin B or its derivatives, or both among patients with pre-existing ESKD.

Data collection and analysis: Two authors independently assessed study eligibility, risk of bias and extracted data. Results were reported as risk ratio (RR) or risk differences (RD) with 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) with 95% CI for continuous outcomes. Statistical analyses were performed using the random-effects model.

Main results: Nine studies compared 1354 participants randomised to either vitamin B or its derivatives with placebo or active control were identified. A total of 1102 participants were randomised to single vitamin B derivatives, placebo or active control in eight studies, and 252 participants randomised to multiple vitamin B derivatives or placebo. Monotherapy included different dose of pyridoxamine (four studies), benfotiamine (1), folic acid (1), thiamine (1), and vitamin B12 (1) while combination therapy included folic acid, vitamin B6, and vitamin B12 in one study. Treatment duration ranged from two to 36 months. Selection bias was unclear in three studies and low in the remaining six studies. Two studies reported blinding of patient, caregiver and observer and were at low risk of performance and detection bias, two studies were at high risk bias, and five studies were unclear. Attrition bias was high in one study, unclear in one study and low in seven studies. Reporting bias was high in one study, unclear in one study, and low in the remaining seven studies. Four studies funded by pharmaceutical companies were judged to be at high risk bias, three were at low risk of bias, and two were unclear.Only a single study reported a reduction in albuminuria with thiamine compared to placebo, while second study reported reduction in glomerular filtration rate (GFR) following use of combination therapy. No significant difference in the risk of all-cause mortality with pyridoxamine or combination therapy was reported. None of the vitamin B derivatives used either alone or in combination improved kidney function: increased in creatinine clearance, improved the GFR; neither were effective in controlling blood pressure significantly compared to placebo or active control. One study reported a significant median reduction in urinary albumin excretion with thiamine treatment compared to placebo. No significant difference was found between vitamin B combination therapy and control group for serious adverse events, or one or more adverse event per patient. Vitamin B therapy was reported to well-tolerated with mild side effects in studies with treatment duration of more than six months. Studies of less than six months duration did not explicitly report adverse events; they reported that the drugs were well-tolerated without any serious drug related adverse events. None of the included studies reported cardiovascular death, progression from macroalbuminuria to ESKD, progression from microalbuminuria to macroalbuminuria, regression from microalbuminuria to normoalbuminuria, doubling of SCr, and quality of life. We were not able to perform subgroup or sensitivity analyses or assess publication bias due to insufficient data.

Authors' conclusions: There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD. Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination. These findings require further confirmation given the limitations of the small number and poor quality of the available studies.

PubMed Disclaimer

Conflict of interest statement

  1. Amit D Raval: none known

  2. Divyesh Thakker: none known

  3. Arohi N Rangoonwala: none known

  4. Deval Gor: none known

  5. Rama Walia: none known

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 1 All‐cause mortality.
1.2
1.2. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 2 Creatinine clearance.
1.3
1.3. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 3 Serum creatinine.
1.4
1.4. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 4 Proteinuria.
1.5
1.5. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 5 GFR.
1.6
1.6. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 6 Patients requiring dialysis.
1.7
1.7. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 7 Systolic blood pressure.
1.8
1.8. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 8 Diastolic blood pressure.
1.9
1.9. Analysis
Comparison 1 Vitamin B versus placebo, Outcome 9 One or more adverse events per patient.
2.1
2.1. Analysis
Comparison 2 Vitamin B versus active control, Outcome 1 Serum creatinine.
2.2
2.2. Analysis
Comparison 2 Vitamin B versus active control, Outcome 2 UAE.
2.3
2.3. Analysis
Comparison 2 Vitamin B versus active control, Outcome 3 Systolic blood pressure.
2.4
2.4. Analysis
Comparison 2 Vitamin B versus active control, Outcome 4 Diastolic blood pressure.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009403

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Agha 2009 {published data only}
    1. Agha A, Amer W, Anwar E, Bashir K. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases & Transplantation 2009;20(3):429‐35. [MEDLINE: ] - PubMed
Alkhalaf 2010 {published data only}
    1. Alkhalaf A, Klooster A, Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010;33(7):1598‐601. [MEDLINE: ] - PMC - PubMed
DIVINe Study 2010 {published data only}
    1. House AA, Ehasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology 2009;20:80A. [CENTRAL: CN‐00740523]
    1. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303(16):1603‐9. [MEDLINE: ] - PubMed
Lewis 2012 {published data only}
    1. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology 2012;23(1):131‐6. [MEDLINE: ] - PMC - PubMed
PYR‐205 Study 2007 {published data only}
    1. McGill JB, Williams ME, Degenhardt TP, Szabo JR, Schotzinger RJ, PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology 2004;15(Oct):565A.
    1. Wassenberg JJ, Fox W, Degenhardt TP, Szabo J, Khalifah RG. Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology 2004;15(Oct):729A.
    1. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology 2007;27(6):605‐14. [MEDLINE: ] - PubMed
PYR‐206 Study 2007 {published data only}
    1. Bell DS, Degenhardt TP, Szabo JR, Khalifah RG, Schotzinger RJ, PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes 2004;53(Suppl 2):A119.
    1. Wassenberg JJ, Knight ST, Fox JW, Degenhardt TP, Szabo J, Khalifah RG. The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology 2003;14(Nov):395A.
    1. Williams ME, Bolton WK, Degenhardt TP, Schotzinger R. A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology 2003;14(Nov):7A.
    1. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology 2007;27(6):605‐14. [MEDLINE: ] - PubMed
PYR‐207 Study 2007 {published data only}
    1. McGill JB, Williams ME, Degenhardt TP, Szabo JR, Schotzinger RJ, PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology 2004;15(Oct):565A.
    1. Wassenberg JJ, Fox W, Degenhardt TP, Szabo J, Khalifah RG. Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology 2004;15(Oct):729A.
    1. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology 2007;27(6):605‐14. [MEDLINE: ] - PubMed
Rabbani 2009 {published data only}
    1. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia 2009;52(2):208‐12. [MEDLINE: ] - PubMed
Wotherspoon 2008 {published data only}
    1. Wotherspoon F, Laight DW, Turner C, Meeking DR, Allard SE, Munday LJ, et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice 2008;62(4):569‐74. [MEDLINE: ] - PubMed

References to studies excluded from this review

Ardalan 2003 {published data only}
    1. Ardalan MR, Etemadi J, Mortazavi M, Majidi J. Hyperhomocysteinaemia therapy in haemodialysis patients with combination of Vitamin B6, B12 and folic acid [abstract no: W467]. Nephrology Dialysis Transplantation 2003;18(4):696. [CENTRAL: CN‐00716091]
    1. Ardalan MR, Mortazavi M, Etemadi J. Hyperhomocysteinemia and its therapy in renal transplant recipients with combination of: Vit B6, Vit B12 and folic acid [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):509‐10. [CENTRAL: CN‐00444217]
Arnadottir 2003 {published data only}
    1. Arnadottir M, Hultberg B. The effect of vitamin B12 on total plasma homocysteine concentration in folate‐replete hemodialysis patients. Clinical Nephrology 2003;59(3):186‐9. [MEDLINE: ] - PubMed
Azadibakhsh 2009 {published data only}
    1. Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients. Saudi Journal of Kidney Diseases & Transplantation 2009;20(5):779‐88. [MEDLINE: ] - PubMed
Biagini 2002 {published data only}
    1. Biagini M, Bertoni E, Marcucci R, Zanazzi M, Rosati A, Fedi S, et al. Vitamin supplementation reduces the progression atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami, FL. 2002. [CENTRAL: CN‐00415280] - PubMed
Bostom 1996 {published data only}
    1. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, et al. High dose‐B‐vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney International 1996;49(1):147‐52. [MEDLINE: ] - PubMed
Brensing 2003 {published data only}
    1. Brensing KA, Hages M, Raab P, Pietrzik K, Bergmann K, Frotscher U, et al. Vitamin B12 and folic‐acid as intravenous high‐dose vitamin therapy for hyperhomocysteinemia in hemodialysed ESRD‐patients: data of a prospective randomized controlled study [abstract no: SU‐PO1048]. Journal of the American Society of Nephrology 2003;14(Nov):766A. [CENTRAL: CN‐00644257]
Chang 2007 {published data only}
    1. Chang TY, Chou KJ, Tseng CF, Chung HM, Fang HC, Hung YM, et al. Effects of folic acid and vitamin B complex on serum C‐reactive protein and albumin levels in stable hemodialysis patients. Current Medical Research & Opinion 2007;23(8):1879‐86. [MEDLINE: ] - PubMed
Cheng 2008 {published data only}
    1. Cheng SC, Young DO, Delmez JA, Coyne DW. The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology 2007;18(Abstracts):924A.
    1. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double‐blind, placebo‐controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(4):1131‐38. [MEDLINE: ] - PMC - PubMed
Chiu 2009 {published data only}
    1. Chiu YW, Chang JM, Hwang SJ, Tsai JC, Chen HC. Pharmacological dose of vitamin B12 is as effective as low‐dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients. Renal Failure 2009;31(4):278‐83. [MEDLINE: ] - PubMed
De Angelis 2007 {published data only}
    1. Angelis S, Noce A, Dessi M, Pastore A, Scaccia F, Trombetta M, et al. Hyperhomocysteinemia and alternate vitamin supplementation [Iperomocisteinemia nei pazienti uremici: effetti della supplementazione alternata di acido folico e vitamina B 12]. Giornale Italiano di Nefrologia 2007;24(1):51‐5. [MEDLINE: ] - PubMed
Dierkes 2001 {published data only}
    1. Dierkes J, Domrose U, Bosselmann KP, Neumann KH, Luley C. Homocysteine lowering effect of different multivitamin preparations in patients with end‐stage renal disease. Journal of Renal Nutrition 2001;11(2):67‐72. [MEDLINE: ] - PubMed
Dobronravov 2008 {published data only}
    1. Dobronravov V, Ardebili M, Golubev R, Galkina O, Nabokow A, Kliem V, et al. The effect of IV administration of sodium 2,3‐dimercaptopropane‐1‐sulfonate (DMPS) and 8‐week high‐dosed IV vitamin B therapy on total plasma homocysteine (tHcy) in patients undergoing chronic hemodialysis (HD) [abstract no: PUB584]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):943A. [CENTRAL: CN‐00758243]
Ducloux 2002 {published data only}
    1. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, et al. Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrology Dialysis Transplantation 2002;17(5):865‐70. [MEDLINE: ] - PubMed
    1. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, et al. Hyperhomocysteinemia therapy in hemodialysis (HD) patients: folinic versus folic acid in combination with vitamin B6 and B12 [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):354A‐5A. [CENTRAL: CN‐00445156] - PubMed
Farvid 2005 {published data only}
    1. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005;28(10):2458‐64. [MEDLINE: ] - PubMed
Frank 1999 {published data only}
    1. Frank T, Bitsch R, Maiwald J, Stein G. Alteration of thiamine pharmacokinetics by end‐stage renal disease (ESRD). International Journal of Clinical Pharmacology & Therapeutics 1999;37(9):449‐55. [MEDLINE: ] - PubMed
Frank 2000 {published data only}
    1. Frank T, Bitsch R, Maiwald J, Stein G. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfontiamine. European Journal of Clinical Pharmacology 2000;56(3):251‐7. [MEDLINE: ] - PubMed
Gonin 2000 {published data only}
    1. Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri‐Imad F, et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. Journal of Nephrology 2003;16(4):522‐34. [MEDLINE: ] - PubMed
    1. Gonin JM, Sarna A, Loya A, Gonin R, Chassaing C, Wainer I, et al. A double‐blind, controlled study of folate and vitamin therapy for hyperhomocysteinemia in hemodialysis [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):269A. [CENTRAL: CN‐00755224]
Heinz 2009 {published data only}
    1. Heinz J, Dierkes J, Domrose U, Neumann KH, Luley C. Influence of a supplementation with vitamins on morbidity and mortality of ESRD patients: a multi‐center randomly designed double blinded intervention trial; Prismavit ‐ prospective intervention study from Magdeburg with vitamins [abstract]. XIV Lipid Meeting; 2003 Dec 5‐7; Leipzig, Germany. 89. [CENTRAL: CN‐00740532]
    1. Heinz J, Domrose U, Luley C, Westphal S, Kropf S, Neumann KH, et al. Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end‐stage renal disease: design and baseline data of a randomized clinical trial. Clinical Nephrology 2009;71(3):363‐5. [MEDLINE: ] - PubMed
    1. Heinz J, Kropf S, Domrose U, Westphal S, Borucki K, Luley C, et al. B vitamins and the risk of total mortality and cardiovascular disease in end‐stage renal disease: results of a randomized controlled trial. Circulation 2010;121(12):1432‐8. [MEDLINE: ] - PubMed
Henning 2001 {published data only}
    1. Henning BF, Zidek W, Riezler R, Graefe U, Tepel M. Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate. Research in Experimental Medicine 2001;200(3):155‐68. [MEDLINE: ] - PubMed
HOPE‐2 Study 2006 {published data only}
    1. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine 2006;354(15):1567‐77. [MEDLINE: ] - PubMed
    1. Mann JF, Sheridan P, McQueen MJ, Held C, Arnold JM, Fodor G, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease‐‐results of the renal Hope‐2 study. Nephrology Dialysis Transplantation 2008;23(2):645‐53. [MEDLINE: ] - PubMed
    1. Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E, Heart Outcomes Prevention Evaluation (HOPE‐2) Investigators. Homocysteine‐lowering therapy and risk for venous thromboembolism: a randomized trial. Annals of Internal Medicine 2007;146(11):761‐7. [MEDLINE: ] - PubMed
    1. Righetti M. Hopeful for a second HOPE‐2 post hoc analysis. Nephrology Dialysis Transplantation 2008;23(7):2428‐9. [MEDLINE: ] - PubMed
    1. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E, Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine‐lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009;40(4):1365‐72. [MEDLINE: ] - PubMed
Hyndman 2003 {published data only}
    1. Hyndman ME, Manns BJ, Snyder FF, Bridge PJ, Scott‐Douglas NW, Fung E, et al. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end‐stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end‐stage renal disease. Metabolism: Clinical & Experimental 2003;52(2):168‐72. [MEDLINE: ] - PubMed
Isbel 2003 {published data only}
    1. Isbel NM, Reiger K, Hayley CM, Campbell SB, Burke J, Bofinger A, et al. Vitamin B12 is effective in the treatment of hyperhomocysteinaemia in patients with ESRD [abstract no: 58]. Nephrology 2003;8(Suppl 3):A69. [CENTRAL: CN‐00758625]
Klemm 1994 {published data only}
    1. Klemm A, Sperschneider H, Lauterbach H, Stein G. Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment?. Clinical Nephrology 1994;42(5):343‐5. [MEDLINE: ] - PubMed
Kuhlmann 2004 {published data only}
    1. Kuhlmann MK, Obeid R, Herrmann W. Normalization of plasma homocystein (Hcy) levels in hyperhomocysteinemic hemodialysis patients by intravenous dosage of vitamins B6, B12 and folic acid [abstract no SA‐PO345]. Journal of the American Society of Nephrology 2004;15(Oct):377A. [CENTRAL: CN‐00757352]
Libetta 2004 {published data only}
    1. Libetta C, Villa G, Gori E, Zucchi M, Pisacco P, Bezoari G, et al. Vitamins supplementation effectiveness on hyperhomocysteinemia in hemodialyzed patients: a two‐year single‐blind randomized study [abstract no: SA‐PO344]. Journal of the American Society of Nephrology 2004;15(Oct):377A. [CENTRAL: CN‐00626027]
    1. Libetta C, Villa G, Gori E, Zucchi M, Sepe V, Pisacco P, et al. Effect of folate or folate plus vitamins B6 and B12 on hyperhomocysteinemia in hemodialyzed patients: a 2‐year controlled randomized study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 126. [CENTRAL: CN‐00636150]
Manns 2001 {published data only}
    1. Manns B, Hyndman E, Burgess E, Parsons H, Schaefer J, Snyder F, et al. Oral vitamin B(12) and high‐dose folic acid in hemodialysis patients with hyper‐homocyst(e)inemia. Kidney International 2001;59(3):1103‐9. [MEDLINE: ] - PubMed
Manrique 2005 {published data only}
    1. Manrique J, Errasti P, Orbe J, Paramo JA, Rodriguez JA. Folic acid and B vitamins improve hyperhomocysteinemia‐induced cardiovascular risk profile in renal transplant recipients. Journal of Thrombosis & Haemostasis 2007;5(5):1072‐6. [MEDLINE: ] - PubMed
Marcucci 2002 {published data only}
    1. Bertoni E, Rosati A, Zanazzi M, Marcucci R, Fedi S, Abbate R, et al. Vitamin supplement reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract no: F‐FC055]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):74P. [CENTRAL: CN‐00444418]
    1. Marcucci R, Bertoni E, Zanazzi M, Rosati A, Fedi S, Rogolino A, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):31. [CENTRAL: CN‐00520363] - PubMed
    1. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, et al. Homocysteine‐lowering therapy and carotid intima‐media thickness in renal transplant recipients. Transplantation Proceedings 2005;37(6):2491‐2. [MEDLINE: ] - PubMed
    1. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal‐transplant recipients. Transplantation 2003;75(9):1551‐5. [MEDLINE: ] - PubMed
    1. Rosati A, Bertoni E, Zanazzi M, Marcucci R, Fedi S, Castellani S, et al. Vitamin supplement reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):510. [CENTRAL: CN‐00447462] - PubMed
Mazdeh 2005 {published data only}
    1. Abolghasemi R, Mazdeh MM, Khatami M, Lessan‐Pezeshki M, Ahmadi F, Seifi S, et al. Hyperhomocysteinemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12 [abstract no: MP318]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v307. - PubMed
    1. Mazdeh MM, Abolghasemi R, Khatami M, Lessan‐Pezeshki M, Ahmadi F, Seifi S, et al. Hyperhomocysteinemia therapy in hemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12 [abstract no: W‐PO40014]. Nephrology 2005;10(Suppl 1):A283. [CENTRAL: CN‐00756890]
Meng 2004 {published data only}
    1. Meng WL, Wang RJ, Yu J. Clinical observation on treatment of diabetic peripheral neuphropathy by ginkgo leaf extract combined with active vitamin B12. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2004;24(7):645‐6. [MEDLINE: ] - PubMed
Mydlik 1995 {published data only}
    1. Mydlik M, Derzsiova K. Water and fat soluble vitamins during erythropoietin (EPO) treatment(t) in haemodialyzed patients (HDP) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 504. [CENTRAL: CN‐00509374]
Nakamura 2003 {published data only}
    1. Nakamura T, Hirayama H, Tajiri M, Saionji K, Hata A. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphism influences the efficacy of folic acid (FA) and vitamin b12 (B12) on hyperhomocyteinemia in hemodialysis (HD) patients [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):699‐700. [CENTRAL: CN‐00446896]
Nakhoul 2004 {published data only}
    1. Nakhoul F, Abassi Z, Plawner M, Khankin E, Ramadan R, Lanir N, et al. Comparative study of response to treatment with supraphysiologic doses of B‐vitamins in hyperhomocysteinemic hemodialysis patients. Israel Medical Association Journal: Imaj 2004;6(4):213‐7. [MEDLINE: ] - PubMed
    1. Plawner M, Nakhoul F, Khankin E, Laneer N, Brenner B, Green J. Folic acid and varying doses of B‐vitamines in the treatment of hyperhomocystinemia in hemodialysis patients [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):295A. [CENTRAL: CN‐00644331]
Nascimento 2004 {published data only}
    1. Nascimento MM, Suliman ME, Murayama Y, Nihi M, Hayashi SY, Riella MC, et al. The effect of high‐dose thiamine (B1) and pyridoxine (B6) on advanced glycation end products (AGEs) and oxidative stress markers in HD patients [abstract no: SU‐PO470]. Journal of the American Society of Nephrology 2004;15(Oct):637A. [CENTRAL: CN‐00644272]
    1. Nascimento MM, Suliman ME, Murayama Y, Nihi M, Hayashi SY, Stenvinkel P, et al. Effect of high‐dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo‐controlled study. Journal of Renal Nutrition 2006;16(2):119‐24. [MEDLINE: ] - PubMed
Okada 2000 {published data only}
    1. Okada H, Moriwaki K, Kanno Y, Sugahara S, Nakamoto H, Yoshizawa M, et al. Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on high‐flux haemodialysis and human recombinant erythropoietin. Nephrology Dialysis Transplantation 2000;15(9):1410‐3. [MEDLINE: ] - PubMed
Pastore 2006 {published data only}
    1. Pastore A, Angelis S, Casciani S, Ruggia R, Giovamberardino G, Noce A, et al. Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clinical Chemistry 2006;52(1):145‐8. [MEDLINE: ] - PubMed
Peng 2005 {published data only}
    1. Peng L, Liu Q. A prospective, randomized, placebo‐controlled study to evaluate the effect of combined treatment of folic acid and intravenous B‐complex vitamins on hyperhomocysteinemia in hemodialysis patients [abstract no: W‐PO40032]. Nephrology 2005;10(Suppl 1):A288. [CENTRAL: CN‐00671827]
Polkinghorne 2003 {published data only}
    1. Polkinghorne KR, Zoungas S, Branley P, Villanueva E, McNeil JJ, Atkins RC, et al. A randomised placebo controlled trial of intramuscular vitamin B12 (hydroxyocobalamin) for the treatment of hyperhomocysteinemia in haemodialysis patients [abstract]. Kongres Nasional VIII Annual Meeting Perhimpunan Nefrologi Indonesia; 2002 Oct; Surabaya, Indonesia. 2.5. [CENTRAL: CN‐00447252]
    1. Polkinghorne KR, Zoungas S, Branley P, Villanueva E, McNeil JJ, Atkins RC, et al. A randomized placebo controlled trial of intramuscular vitamin B12 (hydroxyocobalamin) for the treatment of hyperhomocysteinemia in haemodialysis patients [abstract no: SU‐FC267]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):55a. [CENTRAL: CN‐00447251]
    1. Polkinghorne KR, Zoungas S, Branley P, Villanueva E, McNeil JJ, Atkins RC, et al. Randomized, placebo‐controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients. Internal Medicine Journal 2003;33(11):489‐94. [MEDLINE: ] - PubMed
    1. Polkinghorne KR, Zoungas S, Branley P, Villnueva E, McNeil J, Atkins RC, et al. A randomised placebo controlled trial of intramuscular vitamin B12 (hydroxyocobalamin) for the treatment of hyperhomocysteinemia in haemodialysis patients [abstract]. Nephrology 2002;7(Suppl 3):A68.
Righetti 2006 {published data only}
    1. Righetti M. Homocysteine‐lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clinical Chemistry & Laboratory Medicine 2007;45(12):1586‐9. [EMBASE: 2007598900] - PubMed
    1. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine‐lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purification 2006;24(4):379‐86. [MEDLINE: ] - PubMed
Sanchez Alvarez 2005 {published data only}
    1. Sanchez Alvarez JE, Perez Tamajon L, Hernandez D, Alvarez Gonzalez A, Delgado P, Lorenzo V. Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial [Eficacia y seguridad de dos pautas de suplementos vitaminicos sobre los niveles de homocisteina en pacientes en hemodialisis. Ensayo clinico prospectivo y randomizado]. Nefrologia 2005;25(3):288‐96. [MEDLINE: ] - PubMed
    1. Sanchez JE, Molina E, Vega MJ, Hernandez D, Perez L, Garcia R, et al. Sustained effect of two vitamin supplement regimens on hyperhomocysteinemia in maintenance hemodialysis (MHD) patients [abstract no: F‐PO773]. Journal of the American Society of Nephrology 2003;14(Nov):231A. [CENTRAL: CN‐00583425]
Schupp 2008 {published data only}
    1. Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, Heidland A, et al. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn‐Schmiedebergs Archives of Pharmacology 2008;378(3):283‐91. [MEDLINE: ] - PubMed
Sjogren 1979 {published data only}
    1. Sjogren U, Thysell H, Lindholm T. The influence of vitamin B6 supplementation on the bone marrow morphology in patients on regular haemodialysis treatment. A double‐blind study. Scandinavian Journal of Urology & Nephrology 1979;13(1):101‐3. [MEDLINE: ] - PubMed
Spoelstra 2004 {published data only}
    1. Spoelstra‐de MA, Brouwer CB, Terheggen F, Bollen JM, Stehouwer CD, Smulders YM. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia. Netherlands Journal of Medicine 2004;62(7):246‐53. [MEDLINE: ] - PubMed
Thambyrajah 2000 {published data only}
    1. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?. Circulation 2000;102(8):871‐5. [MEDLINE: ] - PubMed
    1. Thambyrajah J, Landray MJ, Townend JN, Wheeler DC. Folic acid decreases plasma homocysteine but does not improve endothelial function in chronic renal failure [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):372A. [CENTRAL: CN‐00583252]
Tremblay 2000 {published data only}
    1. Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Ouimet D, et al. Hyperhomocysteinemia in hemodialysis patients: effects of 12‐month supplementation with hydrosoluble vitamins. Kidney International 2000;58(2):851‐8. [MEDLINE: ] - PubMed
Tungkasereerak 2004 {published data only}
    1. Tungkasereerak P, Chaiyasoot W, Taruangsri P, Leowattana W, Vasuvattakul S, Vareesangthip K, et al. Can folate and vitamin B supplementation reduce total homocysteine levels and atherosclerosis in hemodialysis patients? [abstract no: SA‐PO472]. Journal of the American Society of Nephrology 2004;15(Oct):406A. [CENTRAL: CN‐00583721]
    1. Tungkasereerak P, Ong‐ajyooth L, Chaiyasoot W, Ong‐ajyooth S, Leowattana W, Vasuvattakul S, et al. Effect of short‐term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients. Journal of the Medical Association of Thailand 2006;89(8):1187‐93. [MEDLINE: ] - PubMed
Vrentzos 2001 {published data only}
    1. Vrentzos G, Ganotakis E, Vardakis K, Maliaraki N, Stratigis S, Stilianou K, et al. Effect of vitamin B12 supplementation in serum total homocysteine and folate in patients with end‐stage renal failure [abstract]. Atherosclerosis Supplements 2001;2(2):107. [CENTRAL: CN‐00671820]
Weissgarten 2001 {published data only}
    1. Weissgarten J, Modai D, Oz D, Chen Levy Z, Cohn M, Marcus O, et al. Vitamin B(6) therapy does not improve hematocrit in hemodialysis patients supplemented with iron and erythropoietin. Nephron 2001;87(4):328‐32. [MEDLINE: ] - PubMed
Xu 2005a {published data only}
    1. Xu T, Wang XF, Qu XK, Ye HY, Huang XB, Zhang XP, et al. Treatment of hyperhomocysteinemia and endothelial dysfunction in renal‐transplant recipients with vitamin B. Chung‐Hua Wai Ko Tsa Chih [Chinese Journal of Surgery] 2005;43(14):940‐3. [MEDLINE: ] - PubMed
    1. Xu T, Zhang XW, Qu XK, Ye HY, Huang XB, Zhang XP, et al. Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population. Journal of Urology 2008;179(3):1190‐4. [MEDLINE: ] - PubMed
Young 2009a {published data only}
    1. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International 2009;29(5):562‐7. [MEDLINE: ] - PubMed

References to studies awaiting assessment

NCT00737126 {published data only}
    1. Lavalle FJ. Folic acid administration reduces the progression of microalbuminuria. www.clinicaltrials.gov/ct2/show/NCT00737126 (accessed 11 December 2014).

Additional references

ADA 1999
    1. Gavin JR III, Alberti KG, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22(1 Suppl):S5‐19. [EMBASE: 1999016853]
ADA 2008
    1. American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care 2008;31 Suppl 1:S12‐54. [MEDLINE: ] - PubMed
ADA 2010
    1. American Diabetes Association. Standards of medical care in diabetes ‐ 2010. Diabetes Care 2010;33 Suppl 1:S11‐61. [MEDLINE: ] - PMC - PubMed
Adler 2000
    1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321(7258):412‐9. [MEDLINE: ] - PMC - PubMed
Adler 2003
    1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney international 2003;63(1):225‐32. [MEDLINE: ] - PubMed
ADVANCE 2008
    1. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008;358(24):2560‐72. [MEDLINE: ] - PubMed
Alberti 1998
    1. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998;15(7):539‐53. [MEDLINE: ] - PubMed
Alderson 2003
    1. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney international 2003;63(6):2123‐33. [MEDLINE: ] - PubMed
Appel 2003
    1. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar‐Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003;26(5):1402‐7. [MEDLINE: ] - PubMed
Ayo 1991
    1. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. American Journal of Physiology 1991;261(4 Pt 2):F571‐7. [MEDLINE: ] - PubMed
Babaei‐Jadidi 2003
    1. Babaei‐Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high‐dose thiamine and benfotiamine. Diabetes 2003;52(8):2110‐20. [MEDLINE: ] - PubMed
Bakker 1997
    1. Bakker SJ, Heine RJ, Gans RO. Thiamine may indirectly act as an antioxidant. Diabetologia 1997; Vol. 40, issue 6:741‐2. [MEDLINE: ] - PubMed
Bergfeld 2001
    1. Bergfeld R, Matsumara T, Du X, Brownlee M. Benfotiamin prevents the consequences of hyperglycemia induced mitochondrial overproduction of reactive oxygen species and experimental diabetic retinopathy [abstract]. Diabetologia 2001;44(Suppl 1):A39.
Berhane 2011
    1. Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end‐stage renal disease and death. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(10):2444‐51. [MEDLINE: ] - PMC - PubMed
Bloomgarden 2008
    1. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care 2008;31(4):823‐7. [MEDLINE: ] - PubMed
Bolignano 2014
    1. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007004.pub3] - DOI - PubMed
Booth 1996
    1. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end‐products: comparison with aminoguanidine. Biochemical & Biophysical Research Communications 1996;220(1):113‐9. [MEDLINE: ] - PubMed
Brownlee 2001
    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813‐20. [MEDLINE: ] - PubMed
Caramori 1999
    1. Caramori ML, Gross JL, Pecis M, Azevedo MJ. Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8‐year follow‐up study. Diabetes Care 1999;22(9):1512‐6. [MEDLINE: ] - PubMed
Chaturvedi 2001
    1. Chaturvedi N, Fuller JH, Taskinen MR, EURODIAB PCS Group. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001;24(12):2071‐7. [MEDLINE: ] - PubMed
Chung 2003
    1. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes‐induced oxidative stress. Journal of the American Society of Nephrology 2003;14(8 Suppl 3):S233‐6. [MEDLINE: ] - PubMed
Cohen 1960
    1. Cohen J. A coefficient of agreement for nominal scales. Educational & Psychological Measurement 1960;20:37‐46.
Dahlquist 2001
    1. Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long‐term follow‐up study of childhood onset type‐1 diabetic patients. Nephrology Dialysis Transplantation 2001;16(7):1382‐6. [MEDLINE: ] - PubMed
Dinneen 1997
    1. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non‐insulin‐dependent diabetes mellitus. A systematic overview of the literature. Archives of Internal Medicine 1997;157(13):1413‐8. [MEDLINE: ] - PubMed
Dronavalli 2008
    1. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nature Clinical Practice Endocrinology & Metabolism 2008;4(8):444‐52. [MEDLINE: ] - PubMed
Du 2000
    1. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia‐induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor‐1 expression by increasing Sp1 glycosylation. Proceedings of the National Academy of Sciences of the United States of America 2000;97(22):12222‐6. [MEDLINE: ] - PMC - PubMed
Finglas 1993
    1. Finglas PM. Thiamin. International Journal for Vitamin & Nutrition Research 1993;63(4):270‐4. [MEDLINE: ] - PubMed
Fioretto 1998
    1. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. New England journal of Medicine 1998;339(2):69‐75. [MEDLINE: ] - PubMed
Forbes 2003
    1. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. Journal of the American Society of Nephrology 2003;14(8 Suppl 3):S254‐8. [MEDLINE: ] - PubMed
Gall 1993
    1. Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non‐insulin‐dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993;36(10):1071‐8. [MEDLINE: ] - PubMed
Gall 1997
    1. Gall MA, Hougaard P, Borch‐Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non‐insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997;314(7083):783‐8. [MEDLINE: ] - PMC - PubMed
Goh 2008
    1. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. Journal of Clinical Endocrinology & Metabolism 2008;93(4):1143‐52. [MEDLINE: ] - PubMed
Gross 2005
    1. Gross JL, Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28(1):164‐76. [MEDLINE: ] - PubMed
Hammes 2003
    1. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine 2003;9(3):294‐9. [MEDLINE: ] - PubMed
Hatfield 2005
    1. Hatfield J. Advanced glycation end‐products (AGEs) in hyperglycemic patients. October 2005. www.jyi.org/issue/review‐advanced‐glycation‐end‐products‐ages‐in‐hypergl... (accessed 23 December 2014).
Heilig 1995
    1. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. Journal of Clinical Investigation 1995;96(4):1802‐14. [MEDLINE: ] - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated February 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hovind 2003
    1. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003;26(3):911‐6. [MEDLINE: ] - PubMed
Huijberts 2008
    1. Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes/Metabolism Research Reviews 2008;24 Suppl 1:S19‐24. [MEDLINE: ] - PubMed
Karachalias 2003
    1. Karachalias N, Babaei‐Jadidi R, Ahmed N, Thornalley PJ. Accumulation of fructosyl‐lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin‐induced diabetic rats. Biochemical Society Transactions 2003;31(Pt 6):1423‐5. [MEDLINE: ] - PubMed
KDOQI 2007
    1. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. American Journal of Kidney Diseases 2007;49(2 Suppl 2):S12‐154. [MEDLINE: ] - PubMed
La Selva 1996
    1. Selva M, Beltramo E, Pagnozzi F, Bena E, Molinatti PA, Molinatti GM, et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end‐products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996;39(11):1263‐8. [MEDLINE: ] - PubMed
Levin 2003
    1. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Seminars in Dialysis 2003;16(2):101‐5. [MEDLINE: ] - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine/Public Library of Science 1999;6(7):e1000100. [MEDLINE: ] - PMC - PubMed
Marshall 2004
    1. Marshall SM. Recent advances in diabetic nephropathy. Postgraduate Medical Journal 2004;80(949):624‐33. [MEDLINE: ] - PMC - PubMed
MCSG 1999
    1. Anonymous. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven‐year prospective study. The Microalbuminuria Collaborative Study Group. Diabetic Medicine 1999;16(11):918‐25. [MEDLINE: ] - PubMed
Miettinen 1996
    1. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non‐insulin‐dependent diabetic subjects. Stroke 1996;27(11):2033‐9. [MEDLINE: ] - PubMed
Mogensen 1995
    1. Mogensen CE. Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin‐dependent diabetes mellitus patients. Journal of Diabetes & its Complications 1995;9(4):337‐49. [MEDLINE: ] - PubMed
Mogensen 1999
    1. Mogensen CE. Drug treatment for hypertensive patients in special situations: diabetes and hypertension. Clinical & Experimental Hypertension (New York) 1999;21(5‐6):895‐906. [PUBMED: 10423111] - PubMed
Mollsten 2001
    1. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S. Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care 2001;24(5):805‐10. [MEDLINE: ] - PubMed
Monnier 1999
    1. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long‐term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48(4):870‐80. [MEDLINE: ] - PMC - PubMed
Nishikawa 2000
    1. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404(6779):787‐90. [MEDLINE: ] - PubMed
Palmer 2008
    1. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation 2008;23(4):1216‐23. [MEDLINE: ] - PubMed
Pecis 1994
    1. Pecis M, Azevedo MJ, Gross JL. Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care 1994;17(7):665‐72. [MEDLINE: ] - PubMed
Perry 2004
    1. Perry CA, Renna SA, Khitun E, Ortiz M, Moriarty DJ, Caudill MA. Ethnicity and race influence the folate status response to controlled folate intakes in young women. Journal of Nutrition 2004;134(7):1786‐92. [MEDLINE: ] - PubMed
Ravid 1998
    1. Ravid M, Brosh D, Ravid‐Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Archives of Internal Medicine 1998;158(9):998‐1004. [MEDLINE: ] - PubMed
Remuzzi 1997
    1. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney international 1997;51(1):2‐15. [MEDLINE: ] - PubMed
Riley 1998
    1. Riley MD, Dwyer T. Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin‐dependent diabetes mellitus. American Journal of Clinical Nutrition 1998;67(1):50‐7. [MEDLINE: ] - PubMed
Ritz 1999
    1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine 1999;341(15):1127‐33. [MEDLINE: ] - PubMed
Ruggenenti 1998
    1. Ruggenenti P, Remuzzi G. Nephropathy of type‐2 diabetes mellitus. Journal of the American Society of Nephrology 1998;9(11):2157‐69. [MEDLINE: ] - PubMed
Sawicki 1994
    1. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17(2):126‐31. [MEDLINE: ] - PubMed
Schreeb 1997
    1. Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert‐Remy U, Gleiter CH. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. European Journal of Clinical Pharmacology 1997; Vol. 52, issue 4:319‐20. [MEDLINE: ] - PubMed
Silveiro 1998
    1. Silveiro SP, Costa LA, Beck MO, Gross JL. Urinary albumin excretion rate and glomerular filtration rate in single‐kidney type 2 diabetic patients. Diabetes Care 1998;21(9):1521‐4. [MEDLINE: ] - PubMed
Stratton 2000
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405‐12. [MEDLINE: ] - PMC - PubMed
Thornalley 2005
    1. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Current Diabetes Reviews 2005;1(3):287‐98. [MEDLINE: ] - PubMed
Thornalley 2007
    1. Thornalley PJ, Babaei‐Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50(10):2164‐70. [MEDLINE: ] - PMC - PubMed
Tilton 1992
    1. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes‐induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney International 1992;41(4):778‐88. [MEDLINE: ] - PubMed
Toeller 1997
    1. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997;40(10):1219‐26. [MEDLINE: ] - PubMed
Valk 2011
    1. Valk EJ, Bruijn JA, Bajema IM. Diabetic nephropathy in humans: pathologic diversity. Current Opinion in Nephrology & Hypertension 2011;20(3):285‐9. [MEDLINE: ] - PubMed
Valmadrid 2000
    1. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older‐onset diabetes mellitus. Archives of Internal Medicine 2000;160(8):1093‐100. [MEDLINE: ] - PubMed
Volvert 2008
    1. Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, et al. Benfotiamine, a synthetic S‐acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid‐soluble thiamine disulfide derivatives. BMC Pharmacology 2008;8:10. [MEDLINE: ] - PMC - PubMed
Wang 2010
    1. Wang H, Deng JL, Yue J, Li J, Hou YB. Prostaglandin E1 for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD006872.pub2] - DOI - PubMed
WHO 1980
    1. WHO Expert Committee on Diabetes Mellitus. World Health Organization. Second report. Technical Report Series 646. 1980. whqlibdoc.who.int/trs/WHO_TRS_646.pdf (accessed 12 December 2014).
WHO 1985
    1. WHO Expert Committee on Diabetes Mellitus. Diabetes mellitus. World Health Organization Technical Report Series 727. 1985. whqlibdoc.who.int/trs/WHO_TRS_727.pdf (accessed 12 December 2014).
Wu 2006
    1. Wu S, Ren J. Benfotiamine alleviates diabetes‐induced cerebral oxidative damage independent of advanced glycation end‐product, tissue factor and TNF‐alpha. Neuroscience Letters 2006;394(2):158‐62. [MEDLINE: ] - PubMed
Yim 2001
    1. Yim MB, Yim HS, Lee C, Kang SO, Chock PB. Protein glycation: creation of catalytic sites for free radical generation. Annals of the New York Academy of Sciences 2001;928:48‐53. [MEDLINE: ] - PubMed

References to other published versions of this review

Raval 2011
    1. Raval AD, Gor D, Rangoonwala AN, Thakker D. Vitamin B and/or its derivatives for diabetic kidney disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009403] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources